help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leaffer, D.
Right arrow Articles by Caulfield, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leaffer, D.
Right arrow Articles by Caulfield, J. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PARATHYROID HORMONE

Endocrinology, Vol 136, 3624-3631, Copyright © 1995 by Endocrine Society

ARTICLES

Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH- (1-34)

D Leaffer, M Sweeney, LA Kellerman, Z Avnur, JL Krstenansky, BH Vickery and JP Caulfield
Department of Analytical and Structural Biology, Syntex Discovery Research, Palo Alto, California 94303, USA.

RS-23581, a synthetic analog of human PTH-related protein-(1-34), and the amino-terminal 34 amino acids of bovine PTH [bPTH-(1-34)] increase bone mineral density. We wished to determine how quickly the ultrastructure of the osteogenic cells, i.e. osteoblasts and lining cells, of the cancellous bone of the second lumbar vertebra of ovariectomized rats was altered in response to the initiation and cessation of treatment. Ovariectomized rats were injected daily with 80 micrograms/kg RS-23581, bPTH-(1-34), or vehicle for 19 days. Animals were killed throughout the treatment period and during the ensuing 10 days. By 5 days after the initiation of treatment with either peptide, the cells on the trabecular surface were predominantly (> 90%) osteoblasts, with only a small increase in the total cell number. Throughout the dosing period, the relative area of the cytoplasm of osteogenic cells from rats treated with RS-23581 or bPTH-(1-34) was greater than that of cells from the ovariectomized control group, suggesting a relationship between bone formation and cytoplasmic mass. By 7 days after the cessation of treatment, the trabecular surface was covered predominantly by lining cells without a change in cell number. Thus, these peptides apparently promote the osteoblast phenotype; the osteoblasts revert to lining cells after the peptides are withdrawn.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
L. J. Raggatt, L. Qin, J. Tamasi, S. C. Jefcoat Jr., E. Shimizu, N. Selvamurugan, F. Y. Liew, L. Bevelock, J. H. M. Feyen, and N. C. Partridge
Interleukin-18 Is Regulated by Parathyroid Hormone and Is Required for Its Bone Anabolic Actions
J. Biol. Chem., March 14, 2008; 283(11): 6790 - 6798.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Y.-H. Wang, Y. Liu, and D. W. Rowe
Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E594 - E603.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Lotinun, J. D. Sibonga, and R. T. Turner
Evidence that the Cells Responsible for Marrow Fibrosis in a Rat Model for Hyperparathyroidism Are Preosteoblasts
Endocrinology, September 1, 2005; 146(9): 4074 - 4081.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanley, S. T. Harris, D. L. Kendler, M. R. McClung, P. D. Miller, W. P. Olszynski, et al.
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Endocr. Rev., August 1, 2005; 26(5): 688 - 703.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Bellido, A. A. Ali, L. I. Plotkin, Q. Fu, I. Gubrij, P. K. Roberson, R. S. Weinstein, C. A. O'Brien, S. C. Manolagas, and R. L. Jilka
Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts: A PUTATIVE EXPLANATION FOR WHY INTERMITTENT ADMINISTRATION IS NEEDED FOR BONE ANABOLISM
J. Biol. Chem., December 12, 2003; 278(50): 50259 - 50272.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. C. Manolagas
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis
Endocr. Rev., April 1, 2000; 21(2): 115 - 137.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
H. Dobnig and R. T. Turner
The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1-34) on Bone Histomorphometry and Serum Chemistry in Rats
Endocrinology, November 1, 1997; 138(11): 4607 - 4612.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Miao, X.-K. Tong, G. K. Chan, D. Panda, P. S. McPherson, and D. Goltzman
Parathyroid Hormone-related Peptide Stimulates Osteogenic Cell Proliferation through Protein Kinase C Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway
J. Biol. Chem., August 17, 2001; 276(34): 32204 - 32213.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society